# Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis D

## TL;DR

Treatment with bulevirtide reduces portal hypertension in chronic hepatitis D patients who respond to the therapy.

## Contribution

Shows that bulevirtide treatment reduces portal hypertension only in patients meeting specific treatment response criteria.

## Key findings

- Bulevirtide significantly decreased hepatic venous pressure gradient in responders but not in non-responders.
- Combined response patients showed complete HVPG response and improved biomarkers of inflammation and endothelial dysfunction.
- Bulevirtide treatment improved clinical and biological markers only in patients meeting defined response criteria.

## Abstract

Portal hypertension (PH) drives decompensation in patients with advanced chronic liver disease. Effects of antiviral treatment with bulevirtide (BLV) and achievement of suggested treatment endpoints on PH in patients with chronic hepatitis D (CHD) are unknown.

BLV-treated CHD patients with PH were prospectively enrolled in this observational, multicenter study. Hepatic venous pressure gradient (HVPG) was measured before (BL) and after ≥12 months of BLV treatment (M12). HVPG response (≥10% decline) rates were compared between virological (VR), biochemical (BR), and combined (CR) responders vs. non-responders as defined in the BLV phase III studies. Associated changes in biomarkers of bacterial translocation, (dys)angiogenesis/endothelial dysfunction, and systemic inflammation (SI) were investigated.

Of 34 patients receiving BL HVPG measurement, 20 patients with paired HVPG measurement and a BL clinically significant portal hypertension (CSPH) (≥10 mmHg HVPG) prevalence of 85% were included. At M12, HVPG significantly decreased in patients with CR (n = 12; 15.5 [IQR 10.5–21.8] to 12 [IQR 7.3–15.8] mmHg; p <0.001), VR (n = 14; 14.5 [IQR 10–21.3] to 12 [IQR 7.8–16.5] mmHg, p = 0.003), and BR (n = 16; 12.5 [IQR 10–20.5] to 10.5 [IQR 8–15] mmHg, p = 0.002); but not in non-responders. All patients with CSPH with CR (n = 10/10) and most of VR (83%, n = 10/12) and BR (85%, n = 11/13) achieved HVPG response, but no BLV non-responder. CSPH resolved in three of 17 (17.6%) patients. Markers of bacterial translocation (sCD163; p = 0.001), (dys)angiogenesis/endothelial dysfunction (Ang2; p = 0.001) and SI (IFNγ, IL-1RA, sCD25/IL-2Rα, CCL3/MIP-1alpha, HGF; all p <0.05) decreased in responders but not in non-responders.

Significant HVPG decreases accompanied by improvement of bacterial translocation, (dys)angiogenesis/endothelial dysfunction and SI are observed in patients with CHD achieving BLV response. These findings provide evidence for the validity and clinical relevance of the currently recommended on-treatment response criteria.

This study is registered at ClinicalTrials.gov (NCT04863703).

Portal hypertension is the main mechanism driving clinical deterioration in patients with compensated advanced chronic liver disease, for which patients with chronic hepatitis D (CHD) are at particularly high risk. This study demonstrates that in patients with CHD with portal hypertension, achieving response to antiviral treatment with bulevirtide decreases the hepatic venous pressure gradient (HVPG). Importantly, a clinical meaningful reduction in HVPG was observed only in treatment responders as defined by endpoints used in clinical trials, in particular, in all patients achieving combined response. Biomarkers of important pathophysiological mechanisms were also improved. The finding of a clinical meaningful HVPG decline in patients with CHD responding to antiviral treatment strengthens the clinical significance of the suggested on-treatment response criteria, supporting a disease-modifying effect of BLV response, likely translating into decreased morbidity and mortality in patients with CHD.

Image 1

•Response to antiviral treatment with bulevirtide ameliorates portal hypertension as measured by HVPG.•A clinically meaningful HVPG reduction occurred only in treatment responders as defined by endpoints used in clinical trials.•All patients with combined response showed a clinically meaningful HVPG response.•These findings reinforce the clinical relevance of the proposed on-treatment response criteria for bulevirtide therapy.

Response to antiviral treatment with bulevirtide ameliorates portal hypertension as measured by HVPG.

A clinically meaningful HVPG reduction occurred only in treatment responders as defined by endpoints used in clinical trials.

All patients with combined response showed a clinically meaningful HVPG response.

These findings reinforce the clinical relevance of the proposed on-treatment response criteria for bulevirtide therapy.